非上市公司路演专场（分会场5））

返回主日程
14:00 - 17:40
  • 主持人 Moderator
  • 李佳璇, 芬兰共和国驻华大使馆高级商务官员
  • Sanorita LI, Senior Advisor, Embassy of Finland, Beijing
14:00 - 14:20
  • 项目1
  • Project 1
  • ABP1011T和ABP1019A小分子多靶点TKI抗癌新药
  • Small-molecule, Multi-target TKI Anticancer Drugs: ABP1011T and ABP1019A
  • 赵宏, 苏州映辉医药科技有限公司BD总监
  • James ZHAO, BD Director of Suzhou Infinory Pharmaceutical Technology Co., Ltd.
14:20 - 14:40
  • 项目2
  • Project 2
  • 弘合生物自研1.1类创新药KH617的进展
  • Development of First-in-Class Drug KH617 by Honghe Biotechnology
  • 王黎明, 北京远鉴信息技术有限公司董事长
  • WANG Liming, Chairman of Beijing Yuanjian Information Technology Co., Ltd.
14:40 - 15:00
  • 项目3
  • Project 3
  • 基于活细胞化学蛋白质组学技术的新药研发及应用
  • Chemoproteomic Solutions for Preclinical Development of Innovative Small Molecule Drugs
  • 张丹, 江苏谱新生物医药有限公司联合创始人、联席董事长
  • ZHANG Dan, Co-founder and co-chairman of Jiangsu Hillgene Biopharma Co.,Ltd.
15:00 - 15:20
  • 项目4
  • Project 4
  • 遗传病与出生缺陷三级防控平台
  • Genetic Diseases and Birth Defects Three-Level Prevention and Control Platform
  • 孙英纵, 深度智耀董事会秘书，物质科学联席总经理
  • ,
15:20 - 15:40
  • 项目5
  • Project 5
  • 一种新型眼科玻璃体切割平台及附件
  • A Novel Ophthalmic Vitrectomy Platform and Accessories
  • 叶永泉, 高特佳投资集团执行合伙人
  • YE Yongquan, Executive Partner,GTJA Investment Group
15:40 - 16:00
  • 项目6
  • Project 6
  • 重塑免疫平衡的精准疗法
  • Precision Therapy for Restoring Immune Balance
  • 徐峰, 中国民生银行战略客户部总经理
  • XU Feng, General Manager,Strategic Clients Department,China Minsheng Bank
16:00 - 16:20
  • 项目7
  • Project 7
  • 新型IBD治疗药物：全新GPCRx的口服小分子激动剂
  • Novel IBD Therapeutic Drug: A New Oral Small-Molecule Agonist of GPCRx
  • 任华, 上海生物医药基金合伙人、CFO
  • REN Hua, Partner and CFO,Shanghai Healthcare Capital
16:20 - 16:40
  • 项目8
  • Project 8
  • 晚期HR+/HER2-乳腺癌患者的治疗新选择——小分子口服Pan-Akt抑制剂NTQ1062片的研究进展
  • Novel Therapeutic Option for Patients with Advanced HR+/HER2- Breast Cancer: Research Advances in the Small-Molecule Oral Pan-Akt Inhibitor NTQ1062 tablet
  • 孙锶铭, Royalty Pharma高级副总裁、亚洲区主管
  • Kenneth SUN, Senior Vice President, Head of Asia,Royalty Pharma
16:40 - 17:00
  • 项目9
  • Project 9
  • 一款PK优异、药效显著的潜在BIC泛RAS(ON)抑制剂
  • A Potential Best-in-Class pan-RAS(ON) Inhibitor with Outstanding Oral PK and In vivo Efficacy Data
  • 杨淼, 浩悦资本业务合伙人
  • YANG Miao, Business Partner,HAOYUE CAPITAL
17:00 - 17:20
  • 项目10
  • Project 10
  • 四价重组诺如病毒疫苗（汉逊酵母）
  • Quadrivalent Recombinant Norovirus Vaccine (Hansenula yeast)
  • 费腾, 源壹资本创始人、CEO
  • Owen FEI, Founder and CEO, Genesis Partners
17:20 - 17:40
  • 项目11
  • Project 11
  • 博骥源：聚焦代谢和炎症性疾病的小分子创新药平台
  • Burgeon：A Small-Molecule Innovative Drug Platform Focused on Metabolic and Inflammatory Diseases
  • 苏利文·克伦威尔律师事务所,
  • Sullivan & Cromwell LLP,